Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function.

Neyt S, Vliegen M, Verreet B, De Lombaerde S, Braeckman K, Vanhove C, Huisman MT, Dumolyn C, Kersemans K, Hulpia F, Van Calenbergh S, Mannens G, De Vos F.

Nucl Med Biol. 2016 Oct;43(10):642-9. doi: 10.1016/j.nucmedbio.2016.07.001. Epub 2016 Jul 12.

PMID:
27513813
2.

Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.

Bosgra S, van de Steeg E, Vlaming ML, Verhoeckx KC, Huisman MT, Verwei M, Wortelboer HM.

Eur J Pharm Sci. 2014 Dec 18;65:156-66. doi: 10.1016/j.ejps.2014.09.007. Epub 2014 Sep 28.

PMID:
25261337
3.

Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.

Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG.

Eur J Pharm Sci. 2013 Aug 16;49(5):819-28. doi: 10.1016/j.ejps.2013.06.009. Epub 2013 Jun 24.

PMID:
23806476
4.

In vivo visualization and quantification of (Disturbed) Oatp-mediated hepatic uptake and Mrp2-mediated biliary excretion of 99mTc-mebrofenin in mice.

Neyt S, Huisman MT, Vanhove C, De Man H, Vliegen M, Moerman L, Dumolyn C, Mannens G, De Vos F.

J Nucl Med. 2013 Apr;54(4):624-30. doi: 10.2967/jnumed.112.108233. Epub 2013 Feb 25.

5.

Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.

van de Steeg E, Greupink R, Schreurs M, Nooijen IH, Verhoeckx KC, Hanemaaijer R, Ripken D, Monshouwer M, Vlaming ML, DeGroot J, Verwei M, Russel FG, Huisman MT, Wortelboer HM.

Drug Metab Dispos. 2013 Mar;41(3):592-601. doi: 10.1124/dmd.112.049023. Epub 2012 Dec 17.

PMID:
23248200
6.

In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity.

Greupink R, Nabuurs SB, Zarzycka B, Verweij V, Monshouwer M, Huisman MT, Russel FG.

Toxicol Sci. 2012 Sep;129(1):35-48. doi: 10.1093/toxsci/kfs188. Epub 2012 May 28.

PMID:
22641618
7.

Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP).

Greupink R, Dillen L, Monshouwer M, Huisman MT, Russel FG.

Eur J Pharm Sci. 2011 Nov 20;44(4):487-96. doi: 10.1016/j.ejps.2011.09.009. Epub 2011 Sep 16.

PMID:
21945488
8.

Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application.

Nibourg GA, Huisman MT, van der Hoeven TV, van Gulik TM, Chamuleau RA, Hoekstra R.

Liver Transpl. 2010 Sep;16(9):1075-85. doi: 10.1002/lt.22110.

9.

A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.

van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bodmer D, Br├╝ggenwirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RP, van Zon PH, Vriesman T, Arts N, Lange MB, Oosterwijk JC, Meijers-Heijboer H, Ausems MG, Hoogerbrugge N, Verhoef S, Halley DJ, Vos YJ, Hogervorst F, Ligtenberg M, Hofstra RM.

Hum Mutat. 2006 Jul;27(7):654-66.

PMID:
16683254
10.

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH.

Int J Cancer. 2005 Sep 20;116(5):824-9.

11.

Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2).

Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P.

J Biol Chem. 2003 Jun 27;278(26):23538-44. Epub 2003 Apr 17.

12.

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH.

J Pharmacol Exp Ther. 2003 Feb;304(2):596-602.

PMID:
12538811
13.

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH.

AIDS. 2002 Nov 22;16(17):2295-301.

PMID:
12441801
14.

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O.

Cancer Res. 2002 Nov 1;62(21):6158-64.

15.

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH.

Mol Pharmacol. 2001 Apr;59(4):806-13.

PMID:
11259625
16.

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

Huisman MT, Smit JW, Schinkel AH.

AIDS. 2000 Feb 18;14(3):237-42. Review. No abstract available.

PMID:
10716499
17.

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH.

J Clin Invest. 1999 Nov;104(10):1441-7.

Supplemental Content

Loading ...
Support Center